After a delay in launching Glatopa 40 mg resulted in competition, Momenta Pharmaceuticals (NASDAQ: MNTA)has decided to conduct a strategic review to determine where it should put its limited cash resources -- presumably partnering or selling the remaining less-important assets -- making for a rather abstract first-quarter earnings update.
Momenta Pharmaceuticals Contemplates Its Future
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться